VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis Lucas Vieira dos SantosMarcelo Rocha CruzJoao Paulo da Silveira Nogueira Lima Review 07 May 2015 Pages: 481 - 489
Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival Lingeng LuHongmei ZengWenxue Ma Review 10 May 2015 Pages: 491 - 500
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells Delphine R. BoulbesGaurav B. ChauhanFrancisco J. Esteva Preclinical study 14 May 2015 Pages: 501 - 513
Relevance of βGal–βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients Karin Milde-LangoschDina SchützeUdo Schumacher Preclinical study 15 May 2015 Pages: 515 - 528
Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing Yong WuMarianna SarkissyanJaydutt V. Vadgama Preclinical Study 15 May 2015 Pages: 529 - 539
Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer Shaham BegAbdul K. SirajKhawla S. Al-Kuraya Preclinical study 16 May 2015 Pages: 541 - 553
Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer Hua ZhangNicos AngelopoulosGeorgios Giamas Preclinical study Open access 29 May 2015 Pages: 555 - 568
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer Christoph ScholzU. AndergassenW. Janni Clinical Trial 13 May 2015 Pages: 569 - 576
Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis Ginés Luengo-GilEnrique González-BillalabeitiaFrancisco Ayala de la Peña Clinical Trial 13 May 2015 Pages: 577 - 587
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) Kathryn J. RuddyHao GuoSara M. Tolaney Clinical trial 16 May 2015 Pages: 589 - 596
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study Miguel J. Gil-GilM. BelletJ. Baselga Clinical Trial 16 May 2015 Pages: 597 - 606
Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer Rong LiuQiao-Li LvHong-Hao Zhou Clinical trial 16 May 2015 Pages: 607 - 618
Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes Hee Jin LeeJeong-Ju LeeGyungyub Gong Clinical Trial 26 May 2015 Pages: 619 - 627
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) Virginia G. KaklamaniJacqueline S. JerussWilliam Gradishar Clinical trial 26 May 2015 Pages: 629 - 638
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis William W. L. WongLisa K. HicksKelvin K. Chan Epidemiology 12 May 2015 Pages: 639 - 652
Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry Tehillah S. MenesMary Beth TerrySaundra S. Buys Epidemiology 15 May 2015 Pages: 653 - 660
Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study Reema A. KarasnehLiam J. MurrayChris R. Cardwell Epidemiology 15 May 2015 Pages: 661 - 669
TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family Sonja KappelElisabeth JanschekDaniela Kandioler Epidemiology 16 May 2015 Pages: 671 - 678
Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients Patricia J. HollenPavlos MsaouelRichard J. Gralla Epidemiology 17 May 2015 Pages: 679 - 686
Racial and ethnic differences in risk of second primary cancers among breast cancer survivors Gregory S. CalipErnest H. LawNaomi Y. Ko Epidemiology 27 May 2015 Pages: 687 - 696
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype Ines Vaz-LuisNancy U. LinRachel A. Freedman Epidemiology 29 May 2015 Pages: 697 - 707
Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer Savas D. SoysalIncken B. KilicErgin Kilic Brief Report 16 May 2015 Pages: 709 - 715
Identification of clinically relevant alterations in phyllodes tumor of the breast by amplicon-based next-generation sequencing Julia Y. S. TsangEdna May L. GoGary M. Tse Letter to the Editor 22 April 2015 Pages: 717 - 719
